No data to show
OTCM
PXMD
Market cap1kUSD
Jun 12, Last price
0.00USD
1D
0.00%
1Q
-50.00%
IPO
-100.00%
Name
PaxMedica Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-18m
L+23.56%
CFO
-11m
L+77.37%
Profile
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 16,145 | 10,604 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (16,145) | (10,604) | ||||
NOPBT Margin | ||||||
Operating Taxes | (168) | 4,192 | ||||
Tax Rate | ||||||
NOPAT | (15,977) | (14,797) | ||||
Net income | (18,290) 23.56% | (14,802) 13.56% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (503,891) | 5,988 | ||||
BB yield | 40,031.51% | -33.74% | ||||
| Debt | ||||||
Debt current | 174 | |||||
Long-term debt | ||||||
Deferred revenue | 500 | |||||
Other long-term liabilities | 915 | |||||
Net debt | (4,711) | (1,728) | ||||
| Cash flow | ||||||
Cash from operating activities | (10,769) | (6,071) | ||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | 13,577 | 7,529 | ||||
FCF | (15,977) | (25,110) | ||||
| Balance | ||||||
Cash | 4,711 | 1,902 | ||||
Long term investments | ||||||
Excess cash | 4,711 | 1,902 | ||||
Stockholders' equity | (52,029) | (33,739) | ||||
Invested Capital | 55,914 | 34,021 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,663 | 514 | ||||
Price | 0.76 -97.81% | 34.51 | ||||
Market cap | 1,259 -92.91% | 17,746 | ||||
EV | (3,452) | 16,017 | ||||
EBITDA | (16,145) | (10,604) | ||||
EV/EBITDA | 0.21 | |||||
Interest | 9 | 5 | ||||
Interest/NOPBT | ||||||